Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis
Rafael Molina(Hospital Clínic de Barcelona), P. Viladiu(Hospital Santa Caterina), Esther Barreiro(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Rafael Fuentes(Hospital Santa Caterina), Vı́ctor Moreno(Universidad Francisco de Vitoria), Arian Benavides Márquez(Hospital Universitario Son Dureta), Isabel Bover(Hospital Universitari Sant Joan de Reus), Xavier Filella, Joan Borràs(Hospital Universitari Sant Joan de Reus), Nuria Vi ntilde olas, E Canals(Hospital Santa Caterina), Josep M. Aug eacute, Juli Rifà(Hospital Universitario Son Dureta)
Cited by 274
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective
|JNCI Journal of the National Cancer Institute|1995|3.4k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
SNPStats: a web tool for the analysis of association studies
|Bioinformatics|2006|2k